• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.

作者信息

Miaris Nikolaos, Maltezou Maria, Papaxoinis George, Visvikis Anastasios, Samantas Epaminontas

机构信息

3rd Department of Medical Oncology, "Agii Anargiri" General Oncology Hospital of Kifissia, N. Kifissia, Athens, Greece.

Department of Neurology, "Agii Anargiri" General Oncology Hospital of Kifissia, N. Kifissia, Athens, Greece.

出版信息

Clin Genitourin Cancer. 2017 Feb;15(1):e99-e103. doi: 10.1016/j.clgc.2016.08.005. Epub 2016 Aug 10.

DOI:10.1016/j.clgc.2016.08.005
PMID:27601362
Abstract
摘要

相似文献

1
Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.帕唑帕尼治疗转移性肾细胞癌患者并发肾病综合征的后部可逆性脑病综合征：病例报告及文献复习
Clin Genitourin Cancer. 2017 Feb;15(1):e99-e103. doi: 10.1016/j.clgc.2016.08.005. Epub 2016 Aug 10.
2
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.帕唑帕尼相关的伴脑出血的后部可逆性脑病综合征
BMJ Case Rep. 2017 Apr 17;2017:bcr-2016-218221. doi: 10.1136/bcr-2016-218221.
3
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.与帕唑帕尼相关的伴有后部可逆性脑病综合征的子宫肉瘤。
J Clin Pharm Ther. 2021 Feb;46(1):223-226. doi: 10.1111/jcpt.13261. Epub 2020 Oct 12.
4
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.帕唑帕尼致肾细胞癌患者可逆性后部脑病综合征
J Clin Pharm Ther. 2013 Apr;38(2):175-6. doi: 10.1111/jcpt.12031. Epub 2012 Dec 4.
5
Reversible posterior leukoencephalopathy syndrome induced by pazopanib.帕唑帕尼诱导可逆性后部白质脑病综合征。
BMC Cancer. 2012 Oct 22;12:489. doi: 10.1186/1471-2407-12-489.
6
Reversible posterior leukoencephalopathy syndrome induced by axitinib.阿昔替尼诱发的可逆性后部白质脑病综合征
Clin Genitourin Cancer. 2014 Feb;12(1):e33-4. doi: 10.1016/j.clgc.2013.08.008. Epub 2013 Oct 14.
7
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.帕唑帕尼（一种多靶点酪氨酸激酶抑制剂）引起的软组织肉瘤患者的后部可逆性脑病综合征（PRES）：病例报告及文献复习。
Invest New Drugs. 2018 Apr;36(2):346-349. doi: 10.1007/s10637-017-0521-5. Epub 2017 Oct 25.
8
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.成功重新给予帕唑帕尼治疗一名转移性肾细胞癌且曾发生帕唑帕尼诱导的肾病综合征的患者：病例报告。
BMC Nephrol. 2019 Jan 3;20(1):1. doi: 10.1186/s12882-018-1181-1.
9
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.帕唑帕尼和依维莫司交替治疗与连续帕唑帕尼治疗对转移性透明细胞肾细胞癌患者延缓疾病进展的效果比较：ROPETAR 随机临床试验。
JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.
10
TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.TOKIO研究原理与方案：一项II期研究，旨在评估转移性肾细胞癌患者在接受两种酪氨酸激酶抑制剂治疗后使用三线酪氨酸激酶抑制剂的活性和安全性。
Tumori. 2015 Nov-Dec;101(6):701-3. doi: 10.5301/tj.5000335. Epub 2015 Jun 20.

引用本文的文献

1
Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy.帕唑帕尼治疗后出现的后部可逆性脑病综合征
Diseases. 2023 May 23;11(2):76. doi: 10.3390/diseases11020076.
2
Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors.血管内皮生长因子抑制剂所致的心血管毒性
Life (Basel). 2023 Jan 29;13(2):366. doi: 10.3390/life13020366.
3
Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review.安罗替尼治疗小细胞肺癌后出现的后部可逆性脑病综合征：一例报告及文献复习
Front Pharmacol. 2023 Feb 6;14:1126235. doi: 10.3389/fphar.2023.1126235. eCollection 2023.
4
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma.一名嗅神经母细胞瘤患者接受乐伐替尼治疗后出现后部可逆性脑病综合征
Brain Sci. 2022 Dec 23;13(1):33. doi: 10.3390/brainsci13010033.
5
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review.帕唑帕尼作为转移性肾细胞癌伴高钙血症危象和肾功能不全的挽救治疗：一例报告及文献综述
Transl Cancer Res. 2020 Apr;9(4):3012-3017. doi: 10.21037/tcr.2020.02.73.
6
Nephrotic Syndrome and Atypical Posterior Reversible Encephalopathy Syndrome in a Patient with Parkinson's Disease.帕金森病患者合并肾病综合征和非典型后部可逆性脑病综合征
Intern Med. 2022 Jul 1;61(13):2061-2065. doi: 10.2169/internalmedicine.8746-21. Epub 2021 Dec 18.
7
Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of inappropriate secretion of antidiuretic hormone: an incidental or pathophysiological association?帕唑帕尼诱发的后部可逆性脑病综合征伴可能的抗利尿激素分泌不当综合征：偶然关联还是病理生理关联？
Neural Regen Res. 2020 Jun;15(6):1166-1168. doi: 10.4103/1673-5374.270420.
8
Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult: A case report and a review of the literature.成人胃癌患者使用阿帕替尼后发生可逆性后部白质脑病综合征：一例病例报告及文献复习
Medicine (Baltimore). 2019 Nov;98(46):e17787. doi: 10.1097/MD.0000000000017787.
9
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.与乐伐替尼治疗甲状腺癌相关的后部可逆性脑病综合征和应激性心肌病：一例报告及文献复习
Oncotarget. 2018 Jun 15;9(46):28281-28289. doi: 10.18632/oncotarget.25606.
10
Pazopanib-induced Endothelial Injury with Podocyte Changes.帕唑帕尼诱导的内皮损伤伴足细胞改变。
Intern Med. 2018 Apr 1;57(7):987-991. doi: 10.2169/internalmedicine.9576-17. Epub 2017 Dec 21.